Publications dans lesquelles il/elle collabore avec Pablo García Pavía (9)

2023

  1. β3 adrenergic agonist treatment in chronic pulmonary hypertension associated with heart failure (SPHERE-HF): a double blind, placebo-controlled, randomized clinical trial

    European Journal of Heart Failure, Vol. 25, Núm. 3, pp. 373-385

2020

  1. Changes in causes of death and influence of therapeutic improvement over time in patients with heart failure and reduced ejection fraction

    Revista Espanola de Cardiologia, Vol. 73, Núm. 7, pp. 561-568

  2. Clinical characteristics and determinants of the phenotype in TMEM43 arrhythmogenic right ventricular cardiomyopathy type 5

    Heart Rhythm, Vol. 17, Núm. 6, pp. 945-954

  3. Design of the β3-Adrenergic Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure Trial

    JACC: Basic to Translational Science, Vol. 5, Núm. 4, pp. 317-327

  4. Prevalence, clinical profile and prognostic implications of interatrial block in patients admitted for heart failure

    REC: CardioClinics, Vol. 55, Núm. 3, pp. 155-164

2019

  1. Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world

    European Journal of Heart Failure, Vol. 21, Núm. 11, pp. 1383-1397

2018

  1. Performance of Prognostic Risk Scores in Chronic Heart Failure Patients Enrolled in the European Society of Cardiology Heart Failure Long-Term Registry

    JACC: Heart Failure, Vol. 6, Núm. 6, pp. 452-462

2016

  1. Idiopathic Restrictive Cardiomyopathy Is Primarily a Genetic Disease

    Journal of the American College of Cardiology

2013

  1. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long-Term Registry

    European Journal of Heart Failure, Vol. 15, Núm. 10, pp. 1173-1184